Anticancer effects and lysosomal acidification in A549 cells by Astaxanthin from *Haematococcus lacustris*

K. Ramamoorthy¹, Subramanian Raghunandhakumar²*, R.S. Anand³, A. Paramasivam⁴, S. Kamaraj⁵, S Nagaraj¹, Devaraj Ezhilarasan²-⁴, Thangavelu Lakshmi², Kamal Dua ⁶,⁷, Dinesh Kumar Chellappan ⁸, Ashokkumar Veeramuthu⁹

¹Centre for Advanced Studies in Botany, University of Madras (Guindy Campus), Chennai, India-600 025; ²Department of Pharmacology, Saveetha Dental College, Saveetha University, Chennai, India; ³Centre for Biotechnology, Anna University, Chennai - 600 025; ⁴Biomedical Research Unit and Laboratory Animal Centre-Dental Research Cell, Saveetha Dental College, Saveetha University, Chennai, India; ⁵Department of Biotechnology, Periyar University (PG Extension Centre), Dharapuri – 636701; ⁶Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia; ⁷School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle NSW 2308, Australia; ⁸Department of Life sciences, School of Pharmacy, International Medical University, Bukit Jalil, 57000,Kualalumpur, Malaysia; ⁹Department of Chemical Technology, Chulalongkorn University, Bangkok, Thailand; Dr. S. Raghunandhakumar, E-mail: raghanandhakumar@gmail.com *Corresponding Author.

Received October 7, 2020; Revised October 26, 2020; Accepted October 26, 2020; Published November 30, 2020

DOI: 10.6026/97320630016965

The authors are responsible for the content of this article. The Editorial and the publisher has taken reasonable steps to check the content of the article in accordance to publishing ethics with adequate peer reviews deposited at PUBLONS.

Declaration on official E-mail:
The corresponding author declares that official e-mail from their institution is not available for all authors

Declaration on Publication Ethics:
The authors state that they adhere with COPE guidelines on publishing ethics as described elsewhere at https://publicationethics.org/. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.

Abstract:
Astaxanthin (AXN) is known to have health benefits by epidemiological studies. Therefore, it is of interest to assess the effect of AXN (derived from indigenous unicellular green alga *Haematococcus lacustris*) to modulate cell cycle arrest, lysosomal acidification and eventually apoptosis using *in vitro* in A549 lung cancer cells. Natural extracts of astaxanthin were obtained by standardized methods as reported earlier and characterized by standard HPLC and MS. Treatment of A549 cells with AXN (purified fraction) showed significant reduction in cell viability (about 50%) as compared to crude extract at 50µM concentration. Thus, we show the anticancer effects and lysosomal acidification in A549 cells by Astaxanthin from *Haematococcus lacustris* for further consideration. Together, our results demonstrated the anticancer potential of AXN from *Haematococcus lacustris*, which is found to be mediated via its ability to induce cell cycle arrest, lysosomal acidification and apoptotic induction.
Key words: Astaxanthin; Haematococcus lacustris; A549 cells; Apoptosis; Lysosomal acidification.

Background:
Haematococcus lacustris (formerly called as Haematococcus pulvialis) is a freshwater microgreen alga with intrinsic antioxidant property and is reported to confer numerous health benefits [1,2]. Astaxanthin (AXN) (3, 3′-dihydroxy-β, β-carotene 4,4′-dione) is a pigmented carotenoid antioxidant with high biological activity given its potential in food and pharmaceutical industries, as well as in feed industry for the ability to pigment and improve survival rate of aquatic animals. H. lacustris has been used preferably to produce astaxanthin from natural sources, and is known to possess high content of astaxanthin at about 5%, of its dry weight (DW) [3]. Furthermore, the structure of astaxanthin from H. lacustris is similar to those in salmon and other aquatic organisms, making astaxanthin more easily to be absorbed. As a result, many efforts have been focused on production of astaxanthin-rich H. lacustris to exploit its benefits to promote human health and as well in industrial applications [4]. Astaxanthin (AXN) from various microalgae and yeast has been approved by United States FDA as a neutecutical and also as a nutraceutical supplement for about 15 years [5,6]. Studies using various in vitro and animal models documented significant health benefits including mediating immune response [7], inhibiting growth of colorectal cancer cells [8], improving rodent memory functions [9] and protection against UV rays mediated photooxidation, antioxidant and anti-inflammatory functions [2]. In addition, reports suggest that the unique structural properties of AXN endure it to span cell membrane and quenches free radicals thereby serving as a better pharmaceutical agent [10,11]. Notably, natural AXN has been shown to cross blood brain barrier (BBB) and exerts protections against various neurological disorders including Alzheimers Disease (AD) [12] and inhibits growth of various tumors including fibrosarcoma, breast, and prostate cancer cells [8,13]. However, most of the reported correlated the beneficial effects of natural AXN for its antioxidant activity and the mechanistic insight underlying natural AXN remains largely unknown. Therefore, it is of interest to assess the effect of AXN (derived from indigenous unicellular green alga Haematococcus lacustris) to modulate cell cycle arrest, lysosomal acidification and eventually apoptosis using in vitro in A549 lung cancer cells.

Materials and Methods:

Chemicals and Reagents:
Propidium iodide (PI), Acridine orange (AO), Ethidium bromide (ETBR) and Dimethyl sulfoxide (DMSO), 3-[(4, 5-Dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium bromide (MTT) and Acridine orange (AO), ethidium bromide (ETBR) were purchased from Sigma (St. Louis, MO, USA). PMI 1640 medium, fetal bovine serum (FBS) was purchased from Gibco (Carlsbad, CA, USA). FBS was stored at −20°C and then freshly prepared aliquots were used for cell culture complete medium. All the other chemicals used were of analytical grade unless otherwise stated.

Extraction of Astaxanthin:
The two litre of 30 days old culture of H. lacustris grown in BBM medium was taken and centrifuged at 10,000 rpm for 15 minutes. After centrifugation, the supernatant was decanted and the pellets were homogenized in a mortar and pestle using 100% acetone in the ratio of 1:10 v/v and then centrifuged at 8,000 rpm for 10 minutes. The supernatant containing pigments was retained and the pellet was again homogenized in fresh solvent and subsequently centrifuged until the cell pellets became colorless. The combined extracts were concentrated with rotary evaporator at 60°C. The dry solid residue was re-dissolved in acetone for subsequent separation such as TLC and column chromatography technique and the different elutes of the sample were confirmed by spectral and analytical methods with authentic astaxanthin.

HPLC analysis:
The samples were analyzed using LC20AD HPLC (SHIMADZU, Japan) equipped with binary pump, auto sampler and fully automated computer-controlled system with Lab solution chromatography workstation for data analysis. Astaxanthin was separated by chromatographic column inert sustain swift C-18, 4.6mmx150mm- 3 µm, (GL sciences Inc.). 20 µl volume was injected with 1ml/min flow rate at 25°C column temperature under 474nm wavelength with mobile phase consists of acetonitrile/methanol/dichloromethane (80:15:5, v/v/v).

MALDI-LC/MS analysis:
Mass spectra using MALDI-LC/MS ((Bruker Daltonics) with spectrometer, equipped with a nitrogen laser (λ = 337 nm), operated in reflectron, positive ion mode. a-cyano-4-hydroxy-cinnamic acid used as the matrices with three independent sample spotting along with Astaxanthin standard samples in ratio of 1:1 (0.5 µl of sample; 0.5 µl of matrix) were spotted on stainless steel MALDI-LC/MS 324 well plate from Bruker Daltonics.
**Cell line and culture:**
Human lung cancer cell line A549 were purchased from National centre for cell science (NCCS), Pune. Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% Antibiotic-Penicillin streptomycin solution. Cells were maintained at a controlled condition of 5% CO₂ and 95% humidity. Experiments were performed in 6-well plates and 96 well plates unless stated otherwise. Cells were seeded at a density of 1 × 10⁶ and 1 × 10⁴ cells per well and incubated for 24 h prior to the experiments. The cells were washed with (phosphate buffered saline, pH 7.4) PBS and incubated in fresh medium containing different concentrations of AXN.

**Cytotoxicity assay:**
Effect of AXN (dose dependent) on cell viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye reduction was performed according to our previous procedure [14]. Finally, the concentrations of AXN resulting in 50% reduction in cell viability at 24h (i.e., 50µM/ml) were then calculated and were used for further experiments. Results were expressed as mean of three independent experiments.

**Acridine orange Ethidium bromide staining:**
AO/EB double staining was performed using standardized methods as previously reported [15]. A549 cells from all the experimental groups were stained using AO (4 µg/ml) and ETBR (4 µg/ml) for 15 min. Followed by incubation-stained cells were examined under the fluorescence microscope using red and green filters. Viable cells will exhibit uniform bright green nuclei denoting normal structure, whereas early apoptotic cells will exhibit green nuclei, but will be more condensed. Late apoptotic cells will show orange to red nuclei with condensed chromatin, while the necrotic cells will show orange to red nuclei with basal chromatin levels.

**Statistical analysis:**
All the experiments were performed independently as triplicates (n=3). The mean ± standard deviation (SD) was determined for each group. One-way analysis of variance (one-way ANOVA) and Tukeys’ test was used for statistical analysis. Statistical value of p <0.05 was used for considering statistical difference between groups.

**Results:**
**Identification and Characterization of AXN:**
The extracted AXN (Crude & Purified) from H. lacustris was identified, characterized, validated and finally confirmed with MALDI-LC/MS and HPLC analysis. The structure and molecular weight based characterization and determination of sample content between crude and purified AXN was clearly mentioned in Figure 1 & 2. In order to characterization of AXN, the levels of stability, linearity, precision and reproducibility and refractory period of experiments were followed by standard analytical laboratory procedure.

**Cytotoxicity assay:**
Treatment of crude and AXN purified fractions from H. lacustris induced significant (P<0.05) cell death in A549 lung cancer cells. Cell death was observed within 24 hours of treatment with the crude and purified fractions of AXN, while control AXN (standard) was also producing similar cell death at 50 µM treatment concentrations in both the cell lines studied (Figure 3A).

**AXN induces nuclear morphology changes by lysosomal acidification:**
Considering that AXN induces a G2/M phase arrest blocking the progression of cell growth and replication, it is obvious to expect deregulated orchestration in the intracellular organelle functions including lysosomes. Indeed, Lysosomes are reported to play important role in all forms of cell deaths (apoptosis, autophagy and necrosis) associated with cancer [16]. We evaluated the changes in lysosomal acidification using acridine orange staining in A549 cells treated with crude and purified AXN fraction from H. lacustris and compared it with control and pure AXN positive control. The staining revealed that both purified AXN fraction and positive controls induced significant (P< 0.05) lysosomal acidification as observed by the increase in red intensity within the cells (Figure 3B).
Figure 1: The HPLC analysis of astaxanthin extracted samples: crude (B), purified (C) from *H. lacustris* and standard astaxanthin substance (A) with respective of three independent experiments.
Figure 2: MALDI-LC/MS spectra with matrices of (a) unknown compound isolated and purified from *H. lacustris* and (b) standard AXN substance were observed in LC/MS. A peak at m/z at 596 – 597 has shown from both unknown and known standard of AXN.

**Discussion:**
Cancer mediated death in global population remains at top for several decades while there is continuous approval for array of anticancer drugs by FDA. About 59 new drugs in 2018 and 46 new drugs in 2017 were approved by FDA, denotes the need for new therapies that can reduce oncology-associated pathologies [17]. Though there are several synthetic drugs that hit global market for oncology therapies, imputability of adverse reactions of the same remains inevitable [18]. Hence, the avenue for safer anticancer drugs with minimal adverse reactions remains open and the agents derived from natural sources possess significant benefits as evident from accumulating reports [19,20]. AXN from *H. lacustris* has been known to possess diverse biological functions including anticancer actions. Other studies using AXN from natural sources already documented its anticancer effects against breast [21], Oral [22], bladder [23], colon [24] and liver [25] however its underlying mechanisms remain to be elucidated. Here we have attempted to investigate the effect of AXN on cell cycle arrest and cellular organelle dysfunction which can be attributed to its anti cancer activity. Although, many carotenoids have been reported to exert
anti cancer and antiproliferative effects, its potential use at clinical stages need to be validated. This could be due to the fact that studies so far conducted failed to establish how AXN affects cellular process or to establish a single prime mode of its anti-cancer action.

In this study AXN treatment altered viability of A549-lung cancer cells. Viability was reduced up to 50% at 50µM concentration of purified AXN. However, time kinetics of purified AXN did not show any changes in loss of viability after 24 hrs (Data not shown).

Figure 3 (A) Shows the cell viability analysis by MTT assay. A549 cells were seeded onto each well and allowed to grow overnight. Cells were treated with various concentration of AXN (crude, Purified and standard AXN) for 24 h and the inhibitory concentration (IC₅₀) was determined. Experiments were performed in triplicates, representative images were presented here and the results were expressed as mean ± SD of 3 experiments. * Denotes significant difference from control by student’s t-test (p < 0.01). (B) Shows status of lysosomal acidification (via pore formation and cytotoxicity) in A549 cells. Cells were treated with and without AXN 50 µM (crude, Purified and standard AXN) for 24 h. Control and AXN treated cells were stained with AO/ETBR and the dual staining was examined under fluorescence microscopy (AO: excitation wavelength: 490nm and emission wavelength: 640nm). (ETBR excitation wavelength: 520nm and emission wavelength: 600nm). Presence of bright red fluorescence indicates lysosomal acidification. Results are expressed as mean ± SD for 3 independent experiments. * denotes significant difference from control by student’s t-test (p < 0.01). Magnification: X20, Scale bar: 50µM.
Studies using other plant-derived carotenoids have shown they inhibit cell cycle progression and mediate cell cycle arrest, particularly in the G0/G1 phase of cell cycle [26,27]. Our results showed that AXN treatment to A549 cells caused accumulation of cells in G0/G1 phase, concomitantly reducing the total percentage of cells in G2/M phase as well. Considering the similarities with other studies, it is found that AXN ability to mediate cell viability loss is associated with cell cycle arrest and inhibition of cell proliferation. Similar to our results many studies have correlates the antitumor efficacy of carotenoids for its ability to mediate cell cycle arrest [28,29]. This suggest that cell cycle arrest might be a initial mode of mechanism of antitumor action of AXN as reported in other cancer cells like colon and prostate cells [29,30]. Further to elucidate the phenomenon that lies behind AXNs ability to mediate cell cycle arrest, we have analyzed the status of cellular organelle dysfunction in A549 cells upon AXN treatment. Indeed, lysosomes are critically noted as a crucial cellular organelle during treatment with various anticancer drugs, as it contains numerous hydrases that can be to degrade intra and extracellular materials and is implicated in cell death [31,32]. Notably, involvement of lysosomes in cell death has been overlooked because lysosomal membrane permeabilization (LMP) due to lysosomal acidification does not alter its ultrastructure [33]. Perhaps, studies involving LMP has been recently focused due to development of more assays that analyze LMPs. Various stimuli such as lysosomotrophic detergents, viral proteins and fungal toxins, proteases, lipid and lipid metabolites, and notably ROS were known to modulate LMP thereby causing lysosomal acidification and eventually cell death [34]. In this study, treatment with AXN to A549 cells causes significant increase in acridine orange (AO) staining denotes increased number of acidic autolysosomes as revealed by Fluorescent microscopic analysis. This denotes that AXN mediates lysosomal acidification and thereby causing loss of LMP and releasing cath D hydrolytic enzymes that can act along with caspases to mediate apoptotic cell death. The observed increase in lysosome acidification can be attributed to ability of AXN to generate ROS in cancer cells and can be correlated to its anticancer function. Here we are the first to report AXN induces lysosomal acidification in A549 cells and can be prime mechanism by which it exerts anti cancer role.

Conclusion: We show the anticancer effects and lysosomal acidification in A549 cells by Astaxanthin from Haematococcus lacustris for further consideration.

Conflict of interest: The authors declare that there are no conflicts of interest

Acknowledgments: The authors acknowledge the financial support rendered by UGC (Kothari-PDF), UGC- BSR, Government of India, New Delhi.

References:
[1] Khoo KS et al. Bioreavour Technol. 2019 288:121606. [PMID: 31178260]
[2] Guerin M et al. Trends Biotechnol. 2003 21:210. [PMID: 12727382]
[3] Wayama M et al. PLoS ONE. 2013 8:53618. [PMID: 23326471]
[4] Davinelli S et al. Nutrients. 2018 10:522. [PMID: 29690549]
[5] Visioli F & Artaria C Food Funct. 2017 8:39. [PMID: 27924978]
[6] Ambati RK et al. Mar Drugs. 2014 12:128. [PMID: 24402174]
[7] Park JS et al. Vet Immunol Immunopathol. 2011 144:455. [PMID: 21930306]
[8] Palozza P et al. Cancer Lett. 2009 283:108. [PMID: 19423215]
[9] Zhang X et al. Environ Geochem Health. 2007 29:483. [PMID: 17721823]
[10] Hussein G et al. J Nat Prod. 2006 69:443. [PMID: 16562856]
[11] Zhang L & Wang H Mar Drugs. 2015 13:4310. [PMID: 26184238]
[12] Nagata T et al. Int J Geriatr Psychiatry. 2017 32:1264. [PMID: 27714849]
[13] Nakao R et al. Anticancer Res. 2010 30:2721 [PMID: 20683004]
[14] Koka P et al. Mol Biol Rep. 2018 45:1653. [PMID: 30128626]
[15] Baskic D et al. Cell Biol Int. 2006 30:924. [PMID: 16895761]
[16] Duprez L et al. Microbes Infect. 2009 11:1050. [PMID: 19736861]
[17] Buffery D Am Health Drug Benefits. 2016 9:233. [PMID: 27688835]
[18] Lavan AH et al. Oncologist. 2019 24:e968. [PMID: 30833488]
[19] Jagannathan R ACS Omega. 2019 4:5402. [PMID: 31179404]
[20] Seca AML & Pinto DCGA. Int J Mol Sci. 2018 19:263. [PMID: 29337925]
[21] McCall B et al. Antioxidants (Basel) 2018 7:135. [PMID: 30287735]
[22] Kavitha K et al. Biochim Biophys Acta. 2013 1830:4433. [PMID: 23726989]
[23] Tanaka T et al. Carcinogenesis. 1994 15:15. [PMID: 8293542]
[24] Nagendraprabhu P & Sudhandiran G Invest New Drugs 2011 29:207. [PMID: 19876598]
[25] Raghunandhakumar S et al. Toxicol Lett. 2013 223:60. [PMID: 24012840]
[26] Obermüller-Jevic et al. J Nutr. 2003 133:3356. [PMID: 14608044]
[27] Palozza P et al. Carcinogenesis. 2002 23:11. [PMID: 11756218]
[28] Garg S et al. Mar Drugs. 2019 17:338. [PMID: 31195739]
[29] Karas M et al. Nutr Cancer. 2000 36:101. [PMID: 10798222]
Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article for FREE of cost without open access charges. Comments should be concise, coherent and critical in less than 1000 words.
